John Wiley & Sons heads into its September 3 earnings release with the stock near a multi-month high and options traders suddenly, sharply more defensive than they have been all year.
The options story is the clearest signal this week. The put/call ratio jumped to 0.44 on Tuesday — more than twice its 20-day average of 0.24, and sitting 2.4 standard deviations above that mean. To put that in context, the PCR had been running below 0.15 for most of mid-August, one of the most call-heavy readings of the past year. The single-session reversal is striking: traders who were leaning bullish through options just days ago have pivoted toward hedging, and the timing — one week out from the print — is hard to ignore as coincidence.
The borrow market tells a far calmer story, and that contrast matters. Availability is ample at roughly 262% — meaning there are more than two-and-a-half shares available to lend for every one already borrowed — leaving no pressure on the short side of the ledger. Cost to borrow has edged up about 11% over the week to 0.54%, but that remains unambiguously cheap in absolute terms. Short interest has climbed roughly 7% over the past week to around 4.58 million shares, continuing a trend that has pushed the short position up about 11% over the past month. Even so, with availability this loose and borrow this inexpensive, the incremental short build looks opportunistic rather than urgent — no squeeze dynamics are in play. The ORTEX short score of 68.9 has drifted higher through the week, reaching its highest reading in the 10-day window shown, but ranks in just the 7th percentile on the short score factor relative to the broader universe, suggesting WLY is not a high-conviction short target by any systematic measure.
The Street picture is mixed, but the fundamental backdrop is constructive. The mean analyst price target sits at $68, implying roughly 26% upside from the current $53.89 close — though the most recent analyst data on record is dated mid-July and the last meaningful rating changes are several years old, so that figure should be treated as indicative rather than current. What is fresher: the stock has risen 5.4% on the week and nearly 9% over the past month, extending a year-to-date run that recent ORTEX notes have pegged above 60%. The EV/EBITDA multiple of roughly 6.7x looks undemanding for a publishing business with an improving digital mix. EPS surprise ranks in the 79th percentile of the ORTEX universe — the company has a consistent habit of beating estimates. The dividend score factor sits at the 85th percentile, though the most recent dividend data available is from 2022, so the yield picture requires independent verification.
One ownership detail is genuinely worth flagging. Peter Wiley — a member of the founding family — added 708,273 shares in the most recently reported period, taking his disclosed holding to just under 1.92 million shares or roughly 3.8% of outstanding. That is a meaningful position increase from a name with obvious long-term conviction in the franchise. On the insider side, June 30 saw a cluster of executive sells — including CEO Matthew Kissner disposing of just under 20,000 shares at $48.51 for approximately $968,000 — but the transactions appear linked to award vesting rather than discretionary selling, and the net 90-day insider flow across all transactions is a positive 55,033 shares at a net value of roughly $2.6 million, tilting the balance toward accumulation.
Peers have moved broadly in line with WLY this week. NWSA gained 5.2% and MNTN added 5.8% — suggesting the week's tailwind has been partly sector-wide rather than WLY-specific. The question heading into September 3 is whether the earnings print can justify a stock trading near its highest levels of the year, or whether the sudden spike in put demand reflects well-positioned caution from traders who know something about the setup the daily price action hasn't yet reflected.
See the live data behind this article on ORTEX.
Open WLY on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
